Rectal Indomethacin
Preclinical
Rectal Indomethacin is one of 27 therapeutic programs targeting Pancreatitis. It is currently in Preclinical.
2
Indications
2
Total Trials
2
Active Trials
26
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
33 competitors in Pancreatitis
#DrugCompanyPhaseTrials
1Indocin
CCosette Pharmaceuticals, Inc.
Approved
Voltaren
NovartisApproved
Cysteine Hydrochloride
NovartisApproved
Doribax
ShionogiApproved
Imuran
LLegacy Health System
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Nitrostat
VViatris Specialty LLC
Approved
Esbriet
LLegacy Health System
Approved
Trental
VValidus Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatitis1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Rectal Indomethacin. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- WWestmead Hospital